Terapia Molecular Dirigida/métodos; Neoplasias Gástricas/tratamiento farmacológico; Inhibidores de la Angiogénesis/uso terapéutico; Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico; Receptores ErbB/antagonistas & inhibidores; Humanos; Ensayos Clínicos Controlados Aleatorios como Asunto; Receptor ErbB-2/antagonistas & inhibidores; Neoplasias Gástricas/epidemiología; Neoplasias Gástricas/mortalidad; Análisis de Supervivencia

ADME, absorption, distribution, metabolism, and excretion; Ab, monoclonal antibody; BSC, best supportive care; CHT, chemotherapy; EGFR, epidermal growth factor receptor; GC, gastric cancer; HER2, human epidermal growth factor receptor 2; HER3, human epidermal growth factor receptor 3; MET, mesenchymal epithelial transition factor; NGS, next generation sequencing; NSCLC, non-small cell lung cancer; OR, odds-ratio; OS, overall survival; PARP, poly ADP ribose polymerase; PFS, progression free survival; PI3K, phosphatidylinositide 3-kinases; PRISMA, preferred reporting items for systematic reviews and meta-analyses; RAF, rapidly accelerated fibrosarcoma; RAS, rat sarcoma viral oncogene homolog; RCTs, randomized clinical trials; RR, response rate; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor; VEGFR: VEGF receptor; aGC, advanced gastric cancer; angiogenesis; gastric cancer; mTOR, mammalian target of rapamycin; mTORC, mTOR complex; meta-analysis; randomized clinical trials; systemic chemotherapy; targeted pathways; targeted therapy